摘要
目的探讨阿托伐他汀治疗2型糖尿病的疗效及对C反应蛋白(C-reactive protein,CRP)的影响。方法选择我科2009年2月至2012年3月确诊的2型糖尿病患者作为研究对象,根据治疗方法不同分为治疗组(阿托伐他汀联合胰岛素治疗)及对照组(单纯胰岛素治疗)各36例,观察并记录两组患者治疗前及治疗4、8、16周后的空腹血糖(FBG)、餐后2h血糖(2hPBG)的变化情况,两组患者治疗16周后的总有效率,及两组患者治疗前后的CRP变化情况、不良反应等。结果治疗组与对照组患者治疗前的FBG、2hPBG组间比较未见明显异常(P>0.05),治疗4、8、16周后,两组的FBG、2hPBG均较治疗前及前一时间段明显降低,且治疗组FBG、2hPBG分别较对照组降低更明显,差异具有统计学意义(P<0.05)。治疗16周后治疗组的总有效率(94.44%)明显高于对照组(75.00%),差异具有统计学意义(P<0.05)。治疗组与对照组患者治疗前的CRP组间比较未见明显异常,治疗16周后,两组的CRP均较治疗前明显降低,且治疗组较对照组降低更明显,差异具有统计学意义(t=2.698,P<0.05)。结论阿托伐他汀治疗2型糖尿病疗效确切,控制血糖效果好,其作用机制考虑可能与降低CRP的水平有关,仍需进一步深入的研究。
Objective To investigate th efficacy ore atorvastatin treatment of type 2 diabetes and to explore the impact on C-reactive protein（C-reactive protein, CRP）. Methods Selected 72 cases of type 2 diabetes in our department from February 2009 to March 2012 diagnosed with type 2 diabetes as an object of study, according to the treatment were divided into a treatment group （atorvastatin treatment）and control group （insulin）36 cases, before treatment and after 4, 8, 16 weeks of treatment, fasting blood glucose （FBG）, 2-hour postprandial blood glucose （2hPBG）changes, the total efficiency of the two groups of patients after 16 weeks of treatment, and the two groups CRP changes before and after treatment, adverse reactions were observed and record between the two groups of patients. Results FBG, 2hPBGof Treatment group and control group patients before treatment had no abnormalities, after the treatment 4, 8, 16 weeks, the FBG, 2hPBG of the two groups reduced than before treatment and the previous period significantly, and in the treatment group, The FBG, 2hPBG significantly decreased respectively as compared to the control group, and the difference was statistically significant（P〈0.05）, after treatment 16 weeks, the total efficiency of the treatment group was 94.44%, and the total efficiency of the control group was （75.00%）, the total efficiency of the treatment group was significantly higher than that in the control group, The difference was statistically significant（P 〈0.05）.Between the treatment group and the control group in patients with pre-treatment CRP group showed no abnormalities after 16 weeks of treatment（P〉0.05）, both groups CRP significantly lower than before treatment, and the treatment group significantly decreased compared with the control group, and the difference was statistically significant（t=-2.698, P〈0.05）. Conclusion Atorvastatin statin treatment of type 2 diabetes efficacy exact control of blood glucose effect, considering its mechanism of action ma
出处
《中国医药指南》
2013年第30期314-316,共3页
Guide of China Medicine
关键词
2型糖尿病
阿托伐他汀
C反应蛋白
空腹血糖
餐后2H血糖
Type 2 diabetes
Atorvastatin
C-reactive protein
Fasting glucose
2h postprandial blood glucose
